Promis Neurosciences Inc. has submitted an IND application to the FDA for PMN-310 for the treatment of Alzheimer’s disease. PMN-310 is a monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-β (Aβ) that are believed to be a major driver of AD, as opposed to monomers or plaque.

Respirerx Pharmaceuticals Inc. has entered into...

The editing in human cells and in mice of the survival motor neuron 1 gene (SMN1) restored the levels of SMN protein that the mutation of the SMN2 gene produces in spinal muscular atrophy (SMA). Scientists from the Broad Institute in Boston and The Ohio State University reversed the mutation using the base editing technique. “This base editing approach to treating SMA should be applicable to all SMA patients, regardless of the specific mutation that caused their SMN1 loss,” the lead author David Liu, a professor and director of the Merkin Institute of Transformative Technologies in Healthcare at the Broad Institute of Harvard and MIT, told BioWorld.

Shanghai Institutes for Biological Sciences and Shanghaitech University have identified dopamine D2 receptor and/or 5-HT receptor agonists reported to be useful for the treatment of depression and schizophrenia.